Published in final edited form as:

Cytokine. 2008 May ; 42(2): 179–190. doi:10.1016/j.cyto.2007.12.010.

Slow-Dissociation Effect of Common Signaling Subunit β on IL5 and GM-CSF Receptor Assembly

Tetsuya Ishino, Adrian E. Harrington, Meirav Zaks-Zilberman, Jeffery J. Scibek, and Irwin Chaiken*

Drexel University College of Medicine, Department of Biochemistry and Molecular Biology, 245 North, 15th Street, Mail Stop 497, New College Building, Room 11102, Philadelphia, PA 19102-1192

Abstract

Receptor activation by IL5 and GM-CSF is a sequential process that depends on their interaction with a cytokine-specific subunit α and recruitment of a common signaling subunit β (β_c). In order to elucidate the assembly dynamics of these receptor subunits, we performed kinetic interaction analysis of the cytokine-receptor complex formation by a surface plasmon resonance biosensor. Using the extracellular domains of receptor fused with C-terminal V5-tag, we developed an assay method to co-anchor α and β_c subunits on the biosensor surface. We demonstrated that dissociation of the cytokine-receptor complexes was slower when both subunits were co-anchored on the biosensor surface than when α subunit alone was anchored. The slow-dissociation effect of β_c had a greater impact on GM-CSF receptor stabilization than that of IL5. The effects were abolished by alanine replacement of either Tyr18 or Tyr344 residue in β_c , which together constitute key parts of a cytokine binding epitope. The data argue that β_c plays an important role in preventing the ligand-receptor complexes from rapidly dissociating. This slow-dissociation effect of β_c explains how, when multiple β_c cytokine receptor α subunits are present on the same cell surface, selective β_c usage can be controlled by sequestration in stabilized cytokine- α - β_c complexes.

1. INTRODUCTION

Cytokines exert various biological activities through high affinity interactions with the extracellular regions of receptors on a target cell. These specific interactions initiate a series of events that ultimately result in a fully assembled complex of receptor subunits on the cell surface and intracellular signaling cascades within the cell. Although cytokine receptors vary in both composition and stoichiometry, the cytokine-triggered receptor subunit assembly is a common mechanism of transmitting information across the membrane and of stimulating intracellular signals [1].

Human interleukin-5 (IL5), interleukin-3 (IL3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are predominantly produced by activated T-lymphocytes and regulate myeloid cell development in hematopoiesis [2]. In particular, these cytokines stimulate eosinophil production, function, and survival, and therefore have been correlated with pathogenesis of diverse inflammatory diseases, such as asthma, gastrointestinal, and hypereosinophilic disorders, in which the eosinophil plays a major role [3] [4] [5] [6]. The

*Corresponding author. Telephone: +1-215-762-4197, Fax: +1-215-762-4452, E-mail: Irwin.Chaiken@DrexelMed.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

functions of eosinophils are primarily controlled by IL5, and to a lesser extent by IL3 and GM-CSF [7]. Genetically, these cytokines belong to the interleukin-4 (IL4) gene subfamily, and structurally, they belong to the short-chain cytokine subfamily of the four-helix bundle cytokine family [8]. At the molecular level, IL5, IL3 and GM-CSF mediate their biological effect via receptors that consist of two distinct subunits, a cytokine-specific α subunit and a common β subunit (β c) that transduces cell signaling [9] [10] [11]. The expression of α subunit for IL5 (IL5R α) in humans is restricted to eosinophilic and basophilic lineages, whereas β c subunit and α subunits for IL3 and GM-CSF are expressed on various lineages including eosinophils, basophils, monocyte/macrophages, dendritic cells, and early haematopoietic progenitors [12]. Therefore, IL5, IL3 and GM-CSF elicit similar responses in eosinophils responsive to all three cytokines, and they even compete for binding to the same cell [13].

The signaling subunit β c shared by IL5, IL3 and GM-CSF is functionally analogous to gp130 and IL2 common receptor subunit γ , which are the common signaling subunits shared by various other cytokines responsible for immunological activities and hematopoiesis. These common subunits are known to act not only as signal transducers but also as affinity converters that enhance an initial cytokine-receptor complex into a higher-affinity state. Interestingly, IL5, IL3 and GM-CSF bind to their receptor subunits α with different affinities, while the binding affinities are increased up to a similar value in the presence of β c. Cellular binding assays have shown that β c can enhance the binding affinity 2 to 5-fold in the IL5 system [11] [14], vs 20- to 100-fold for the GM-CSF case [9], and 500- to 1000-fold for the IL3 case [10] [15]. In other words, the effects of β c on affinity enhancement vary depending on the cytokine-receptor systems: GM-CSF and IL3 bind to their α subunits with low affinities and high affinity complexes are formed in the presence of β c, whereas IL5 binds to IL5R α alone with greater affinity and there is relatively smaller affinity enhancement by β c. While a growing body of evidence has accumulated to demonstrate the importance of common receptor subunits as signal-transducing machinery, very little is known about the mechanism of affinity enhancement.

Both α and β c subunits are members of the class I cytokine receptor superfamily, which is characterized by the presence of the so-called cytokine recognition motif (CRM) [16]. The CRM is composed of two fibronectin type III (FnIII) domains, each consisting of ~100 residues with four conserved cysteine residues in the first FnIII domain and a conserved WSXWS (X is any amino acid residue) sequence in the second FnIII domain. The extracellular region of α subunit is composed of three FnIII domains (D1, D2 and D3), of which D2D3 constitutes a CRM. In contrast, the extracellular region of β c is composed of four FnIII domains (D1, D2, D3 and D4), with both D1D2 and D3D4 corresponding to CRMs in the primary sequence [17]. The receptor subunits α for IL5, IL3 and GM-CSF share not only a high degree of amino acid sequence similarity but also the signaling subunit β c, and thus constitute a distinct subgroup (β c family) within the class I cytokine receptor superfamily. Extensive mutational analyses on the binding interfaces of cytokine-receptor complexes in β c family have been carried out over the past decade. In the case of IL5 receptor system, for instance, our recent data have shown that the ligand-binding epitope in IL5R α comprises a cluster of negatively-charged residues (Asp55, Asp56, Glu58) from D1 domain and a cluster of positively-charged residues (Lys186, Arg188, Arg296) from D2 and D3 domains [18]. Although β c itself has no measurable affinity for cytokine in a bimolecular (cytokine- β c) complex [9] [10] [11] [19] [20], it is conceivable that IL5, IL3 and GM-CSF make direct contacts with β c in the high affinity trimolecular (cytokine- α - β c) complex. The ligand-binding epitope in β c appears to be composed of mostly aromatic residues from D1 (Tyr18, Phe82) and D4 (Tyr344, Tyr400) domains [21] [22] [23] [24]. Crystallographic analysis has shown that the extracellular regions of β c exist as a domain-swapped dimer composed of two identical polypeptide chains [25], and that these binding residues are clustered in the interface of D1 and D4, domains from each polypeptide chain, that constitute a CRM in the three dimensional structure [23] [24].

Although mutational analyses and cellular binding assays have provided detailed insights into the static nature of the trimolecular cytokine-receptor interactions in βc family, the dynamic nature of receptor assembly and how this regulates the receptor activation switch have not yet been elucidated. In an attempt to address these questions, we studied interaction kinetics of cytokines with α and βc subunits by using a surface plasmon resonance (SPR) biosensor. We constructed soluble forms (extracellular domains) of IL5R α and βc fused with C-terminal V5 peptide (GKPIPPLLGLDST) tag and developed an anti-V5 antibody surface to anchor both subunits together in an oriented manner. The surface with both subunits had a higher affinity for IL5 binding than that with IL5R α alone. Kinetic data analysis demonstrated that the higher binding affinity of the trimolecular complex formation was predominantly due to the slower dissociation. Furthermore, we constructed a soluble form of GM-CSF receptor α subunit (GMR α) fused with V5-tag and investigated the kinetics of interaction of GM-CSF with GMR α and βc . We found that the slow-dissociation effect had more impact on the GM-CSF system than the IL5 system. These data argue for a role of βc in the dynamics of receptor subunit assembly and activation.

2. MATERIALS AND METHODS

2.1. Materials

Human IL5 protein was prepared as previously described [20]. Human GM-CSF protein was purchased from R&D systems Inc (Minneapolis, MN). All the restriction enzymes were purchased from New England Biolabs Inc (Beverly, MA). The anti HIV gp120 monoclonal antibody (17b) was prepared as previously described [26], and the anti- βc monoclonal antibody (3D7) was purchased from BD Biosciences (San Jose, CA). All the synthetic oligonucleotide primers, anti-V5 antibody, *Drosophila* Schneider 2 (S2) cells, cell culture media, blasticidin S and L-glutamine solution (200 mM) were purchased from Invitrogen Inc (Carlsbad, CA). For surface plasmon resonance measurements, the sensor chip CM5, surfactant P20, N-ethyl-N-(3-dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS), and 1 M ethanolamine (pH 8.5) were purchased from Biacore Inc (Piscataway, NJ).

2.2. Construction of Expression Vectors and Mutagenesis

The DNA fragment containing a soluble form (extracellular domain) of βc (s βc) was amplified from a full length human βc cDNA by iCycler Thermal Cycler (Bio-Rad Laboratories) with Pfu Turbo DNA polymerase (Stratagene). The PCR product was digested with NcoI and ApaI and ligated into the NcoI and ApaI sites of the *Drosophila* expression vector, pMT/Bip/V5-His plasmid (Invitrogen), yielding pMT-s βc -V5-His. In this construct, the gene for s βc was placed downstream of the *Drosophila* methallothionein promoter and the Bip secretion signal sequence. The C-terminus of s βc was linked to V5 peptide and hexahistidine tags. The expression vector for a soluble form of GM-CSF receptor α subunit (sGMR α) was constructed likewise, and denoted pMT-sGMR α -V5-His. The expression vector for a soluble form of IL5 receptor α subunit (sIL5R α) was constructed previously [18].

Alanine substitutions were introduced into pMT-s βc -V5-His by in vitro site-directed mutagenesis. The mutant plasmids were amplified with synthetic oligonucleotide primers of the appropriate base changes by Pfu Turbo DNA polymerase, and the template plasmid was digested by the treatment of DpnI before transformation. All the plasmids created were verified by DNA sequencing.

2.3. Protein Expression

For the transient expression of s βc , sIL5R α or sGMR α , *Drosophila* S2 cells were transfected with the vector pMT-s βc -V5-His, pMT-sIL5R α -V5-His [18], or pMT-sGMR α -V5-His, respectively using Cellfectin reagent (Invitrogen). Protein expression was induced by addition

of 750 μ M copper sulfate 3 days after transfection. Levels of expression were measured by western blot using anti-V5 antibody. The cell-free supernatant was collected by centrifugation and stored at -20°C for subsequent binding analyses.

For the stable cell line expressing s β c, the vector pMT-s β c-V5-His and the blasticidin resistant vector pCoBlast (Invitrogen) were co-transfected into S2 cells using Cellfectin reagent. Blasticidin-resistant cells were selected as a stable polyclonal population and grown in *Drosophila* serum-free medium with 20 mM L-glutamine and 50 μ g/mL blasticidin S. Cells were expanded to 1.0×10^7 cells/mL, and protein expression was induced by addition of 750 μ M copper sulfate. The culture was harvested after 3 days and centrifuged at $1000\times g$ for 15 min. Protein expression was verified by western blot using anti- β c antibody.

2.4. Purification of Soluble β c Protein

The cell-free supernatant including s β c protein was dialyzed against buffer A (50 mM Tris-HCl, pH 7.4, 50 mM NaCl) and loaded onto a HiTrap Chelating HP column (Amersham Biosciences) pre-equilibrated with buffer A. Non-specific binding proteins were washed away with buffer B (50 mM Tris-HCl, pH 7.4, 25 mM imidazole, 300 mM NaCl), and the s β c protein was eluted with a linear gradient from buffer B to buffer C (50 mM Tris-HCl, pH 7.4, 300 mM imidazole). In gel filtration, s β c eluted as a dimer. The pooled fraction was loaded onto Sephacryl-200 (26×600 mm) and eluted in phosphate buffered saline (PBS) buffer (1 mM KH_2PO_4 , 10 mM Na_2HPO_4 , 137 mM NaCl, 2.7 mM KCl, pH 7.4). The resulting protein solution was concentrated and stored below -80°C . The purity was evaluated by SDS-PAGE (4–20% linear gradient gel, Bio-Rad Laboratories). Protein quantitation was achieved by measuring the absorbance at 280 nm and calculating the concentration using the molar absorption coefficient ($\epsilon_{280} = 100,380 \text{ M}^{-1}\text{cm}^{-1}$) according to Pace et al [27].

2.5. Surface Plasmon Resonance Interaction Analysis

The kinetic interaction assay was performed by using a surface plasmon (SPR) biosensor, Biacore 3000 (Biacore, Uppsala, Sweden). All the SPR experiments were conducted at 25°C using PBS plus 0.005% P20 solution as a running buffer.

2.5.1. Immobilization—Anti-V5 antibody was immobilized on a CM5 sensor chip by the amine coupling method. A stock of protein solution (1.1 mg/mL) was diluted 20 times in 10 mM sodium acetate (pH 4.5) and injected onto a carboxymethylated dextran surface which had been pre-activated with a 35 μ L injection of 1:1 mixture of 200 mM EDC and 50 mM NHS, followed by the injection of 1 M ethanolamine-HCl (pH 8.5). The amounts of immobilization were around 5,000 resonance units (RU). Anti-gp120 antibody was immobilized similarly and used as a reference surface.

2.5.2. Binding assay—To anchor receptor proteins on the biosensor surface, the V5-tagged receptor subunits were injected onto the anti-V5 antibody surface. After washing the receptor surface by passing running buffer for 2 min, various concentrations of cytokine were injected over the receptor surface for the measurement of cytokine-receptor interactions. To regenerate chip surfaces, both bound cytokine and anchored receptor were removed from the antibody surfaces by multiple injections of 10 mM glycine-HCl (pH 1.6). For this biosensor assay, all procedures were automated to create repetitive cycles of injection of receptor subunit (10 μ L/min), cytokine (50 μ L/min), and the regeneration buffer (100 μ L/min).

2.5.3. Data analysis—The sensorgrams were analyzed using the BIAevaluation (Biacore) and CLAMP software [28] which employ numerical integration and global fitting algorithms [29]. Prior to the analysis, the binding data were corrected for non-specific interaction by subtracting the reference surface data from the reaction surface data, and further corrected for

buffer effect by subtracting the signal from buffer injections from those of protein sample injections. It has been observed that binding of IL5 to IL5R α is compromised by mass transport effects [18]. Although a relatively fast flow rate (up to 100 $\mu\text{L}/\text{min}$) was used to minimize mass transport effects, they were not eliminated. Thus, the data obtained were globally fit using a simple 1:1 binding model combined with a two-compartment mass transport limitation model unless otherwise stated.

Equilibrium Model (1)

In this model, **IL5₀** and **IL5** represent the concentrations of IL5 protein in the bulk flow layer and the near surface layer, respectively, and k_m represents the transport rate constant between these two layers. **IL5R α** is the immobilized species, and **IL5·IL5R α** is the final complex that is counted as a response in the biosensor. The equilibrium dissociation constant (K_d) was calculated from the association and dissociation rate constants (k_{on} and k_{off}) as $K_d = k_{\text{off}}/k_{\text{on}}$.

For the binding experiments using the mixed-receptor surface of both α and βc subunits, the interaction curves were analyzed using a trimolecular two-step reaction model as well as above simple 1:1 binding model. Since βc does not bind strongly to either IL5 or IL5R α in a bimolecular complex [20], we assumed that IL5 binds to IL5R α and the resulting complex recruits βc . The following equilibrium model was derived for these interactions.

Equilibrium Model (2)

In this model, **IL5** binds to **IL5R α** to form an intermediate complex (**IL5·IL5R α**) similar to simple 1:1 binding, then this complex recruits βc on the surface to form a final complex (**IL5·IL5R α · βc**). We use the symbols k_1 and k_{-1} to denote the association and dissociation rate constants for the first step, while k_2 and k_{-2} denote those for the second step. Individual kinetic parameters were obtained from at least three separate experiments. The kinetic binding data for GM-CSF and its receptor were analyzed in the same way.

3. RESULTS

3.1. Binding of IL5 to Individual Receptor Surfaces

We previously constructed a soluble form (extracellular region) of IL5R α (sIL5R α) fused with V5 peptide tag at its C-terminus to anchor the receptor by anti-V5 antibody on a surface resonance plasmon (SPR) biosensor. Using this assay method, we successfully observed the binding kinetics of the IL5-IL5R α interaction and defined the epitope residues of IL5R α for IL5 binding by alanine-scanning mutagenesis [18]. In the current work, we employed a similar approach to produce a soluble form of β c (s β c) and generated a multi-subunit receptor surface together with α subunits. The encoded protein was designed to contain C-terminal V5 and hexahistidine tags for display on the biosensor surface and purification of proteins, respectively (Fig. 1A). Protein was expressed in S2 cells by addition of copper sulfate and secreted into the culture media at approximately 50 nM. The molecular weight of the purified s β c was estimated by SDS-PAGE analysis to be 54 kDa under both reducing and non-reducing conditions (Fig. 1B), confirming that no intermolecular disulfide bond is formed [25] [30]. The purified product was identified by western blot analysis using anti- β c antibody (Fig. 1B). Production and characterization of V5-tagged sIL5R α were done as previously described [18] [31].

Using the SPR biosensor, we first examined bimolecular binding of IL5 to individual receptor surfaces. V5-tagged protein was selectively anchored by anti-V5 antibody, providing an orientated surface for the subsequent quantitative ligand binding assay. Figure 2A shows the sensorgram and fit data for dose-dependent binding of IL5 to the sIL5R α -anchored surface. The rate constants (k_{on} and k_{off}) were calculated by fitting the association and dissociation phases to a simple 1:1 binding model (Table 1). The rate constants and the equilibrium dissociation constant for the IL5-IL5R α interaction were similar to the values reported previously [18]. We also assessed binding of IL5 to the s β c surface. As previously shown by biochemical and cellular binding assays [19] [20], no significant binding was detected even when the concentration of IL5 was increased up to 2 μ M (Fig. 2B).

3.2. Kinetics of IL5 Binding to Mixed-Receptor Surfaces

In order to define the functional role of β c in IL5 binding to receptor, we examined interaction kinetics of the trimolecular complex by injecting IL5 over the mixed-receptor surface comprised of sIL5R α and s β c. Since IL5 does not bind on its own to β c (Fig. 2B), binding events observed from the mixed-receptor surface can be a composite of the bimolecular (IL5-IL5R α) and the trimolecular (IL5-IL5R α - β c) interactions. To minimize the contribution of the bimolecular interaction, a mixed surface with excess amounts of s β c was formed. We examined an optimum ratio of receptor subunits by varying amounts of s β c with a constant amount of sIL5R α on the anti-V5 antibody surface. The sensorgrams were measured by injecting 10 nM of IL5 over the mixed-receptor surfaces of sIL5R α and s β c in different ratios. We found that dissociation rates became slower with increasing amounts of s β c, indicating that IL5 is bound in a ternary complex with α and β c subunits, while association rate was little affected by the presence of s β c (Fig. 3A). Since there was no further difference in the measured dissociation rates between ratios of 1:3 and 1:9 (IL5R α : β c), we reasoned that the observed sensorgrams at the ratio of 1:3 or more were mostly attributable to the trimolecular interaction. Thus, we chose 1:5 ratio of sIL5R α to s β c for the subsequent trimolecular interaction experiments. Figure 2C shows the sensorgram for dose-dependent binding of IL5 to the mixed-receptor surface. Since we immobilized high density of β c, it is possible that rebinding of IL5 to the mixed-receptor surface would occur in the dissociation phase, which should be eliminated for better model fitting of biosensor data. We examined the rebinding by injecting soluble IL5R α in the dissociation phase and found that soluble IL5R α had no effect on the rate of dissociation of IL5 from the mixed receptor surface (data not shown), indicating that there is no significant rebinding in this system. Although biosensor analysis does not require information on the

stoichiometry of receptor subunits on a biosensor surface to calculate kinetic parameters, it can be assumed that the complex is comprised of one cytokine, one α subunit and one preformed homodimer of β c (Fig. 2C; **lower panel**) as found by analytical ultracentrifugation [30]. We found that IL5 dissociates more slowly from the mixed-receptor surface of sIL5R α and s β c (Fig. 2C) than that of sIL5R α alone (Fig. 2A). For quantitative analysis of the trimolecular interaction, we tested two different models, one for simple 1:1 binding and a second for trimolecular two-step binding (*see Section 2.5.2*). Kinetic evaluation using the 1:1 model demonstrated that the mixed-receptor surface caused a slower association rate (3-fold) and a slower dissociation (6-fold), with resulting slightly higher binding affinity (2-fold) than the sIL5R α surface (Table 1). The tri-molecular two-step model failed to improve the fit. One possible reason for this is that, due to the proximity of α and β c subunits on the sensor surface, these subunits could be already engaged with each other. To test this possibility, IL5 pre-incubated with IL5R α was injected over the mixed receptor surface. We found that binding of IL5 to the α and β c surface was largely reduced by addition of IL5R α (Fig 3B). The possible reasons for subunit pre-engagement on the sensor surface are discussed later. For the purposes of data analysis of the trimolecular interaction SPR sensorgrams, we used the simple 1:1 binding model to derive kinetic parameters.

3.3. Mutational Effect on the IL5-IL5R α - β c Interaction

To verify that the effect of β c on interaction kinetics was due to specific β c interaction, we introduced site-directed mutations into a ligand-binding site in β c. Tyr18 and Tyr344 of β c (corresponding to Tyr15 and Tyr347 in the crystal structure [25]) have been found to be critical for IL5, IL3 and GM-CSF association into their respective trimolecular complexes [21] [22] [23] [24]. These residues are located in a hypothetical ligand-binding interface of D1 and D4 domains (Fig. 4A). Structural integrity of these mutants was previously verified by measuring their cell surface expression with flow cytometry [23] [24]. The two alanine-mutational variants, s β c(Y18A) and s β c(Y344A), were successfully expressed in *Drosophila* S2 cells and secreted into the cell culture in amounts roughly equal to that achieved for wild type s β c protein. This expression of secreted soluble proteins was taken as further verification that these molecules were stably folded. Either s β c(Y18A) or s β c(Y344A) was anchored together with sIL5R α on the anti-V5 antibody surface, and the above kinetic interaction assay was applied to these mutational variants (Fig. 4B). Both mutations resulted in kinetic parameters and binding affinity similar to those obtained for the IL5-IL5R α interaction (Table 1), demonstrating that the effect of β c on the IL5-IL5R α - β c interaction was greatly diminished by these mutations. We concluded that the kinetic effect of β c on trimolecular complex formation was due to the specific interaction between cytokines and β c.

3.4. Kinetics of Interaction between GM-CSF and Receptor Subunits

The interaction of IL5 with IL5R α is already high affinity in the absence of β c, unlike the interactions of IL3 and GM-CSF that become higher affinity only in the presence α and β c subunits together. We therefore sought to determine whether the kinetic effect of β c observed with IL5 also occurs for other β c cytokines such as GM-CSF and, if so, to what magnitude. We produced a soluble form (extracellular domain) of GM-CSF receptor α subunit (sGMR α) fused with V5-tag, and investigated interaction of GM-CSF with GMR α and β c (Fig. 5A). We first examined binding of GM-CSF to sGMR α in the absence of s β c (Fig. 5B). The kinetic parameters were calculated by using a simple 1:1 binding model (Table 1). The kinetic parameters for the interaction between GM-CSF and GMR α (Table 1) were similar to the values that were previously reported using an SPR biosensor [32]. We found that GM-CSF binds to GMR α with 30-fold lower binding affinity than IL5 binding to IL5R α , mostly because of the slower association rate for GM-CSF. We optimized the ratio of receptor subunits on the biosensor surface for GM-CSF system. The slow-dissociation effect of β c also reached a plateau at 1:3 ratio of sGMR α to s β c (data not shown), and therefore we chose the 1:5 ratio as

used for the IL5 system. Figure 5C shows the sensorgram for dose-dependent binding of GM-CSF to the mixed-receptor surface. The binding affinity was 15-fold higher in the presence of s β c, due to the slower dissociation (Table 1). We also measured the binding of GM-CSF to sGMR α in the presence of s β c mutational variants, s β c(Y18A) and s β c(Y344A) (Fig. 5D, E), and found that the enhanced affinity was markedly reduced by these mutations. As expected, GM-CSF did not bind to the β c surface (Fig. 5F).

4. DISCUSSION

4.1. Development of Biosensor Surface to Investigate Receptor Assembly

The goal of this study was to elucidate the dynamic role of the signaling subunit β c in the receptor assembly process of IL5 and GM-CSF. In order to address this goal, we developed an analytical procedure that enables measurement of kinetics of interaction between cytokine and multiple receptor subunits on the surface of an SPR sensor chip. Our previous biosensor analysis using soluble receptor showed that IL5-IL5R α complex binds to the β c-immobilized surface with a low affinity, suggesting a sequential process of IL5-ILR α - β c complex formation [20]. While this configuration of assay was adequate to investigate the direct interaction of IL5-IL5R α complex with β c, we sought to develop an assay method that cytokine binding to α and β subunits in tandem on the biosensor surface. The gold surface on the SPR sensor chip used in this study is covered with a matrix of carboxymethylated dextran that forms a flexible hydrogel. The dextran matrix is known to be mobile enough to allow receptor subunits to assemble by addition of ligand [33] [34]. Here, we introduced a new surface configuration, in which the soluble forms of α and β c were co-anchored through tight interaction between their C-terminal V5-tag and the anti-V5 antibody immobilized on the dextran surface (Fig. 6). We demonstrated that the surface with both α and β c subunits had a higher affinity for ligand binding than that with the α subunit alone, in both IL5 and GM-CSF systems (Fig. 2 and 5). This result is consistent with previous cell binding data [21] (Table 1), supporting the relevance of the biosensor assay configuration to binding events on the cell surface.

In the current study, we utilized simultaneous display of receptor subunits α and β c on an SPR sensor chip surface to enable evaluation of kinetic effects of tandem interaction of cytokine analyte with the receptor subunit combination. We observed that the dissociation rate of IL5 from the sensor surface decreased upon β c incorporation (versus the rate with IL5R α alone). The dissociation rate decrease was β c dose-dependent, and was maximal at a 1:3 ratio of α to β c (Fig. 3A). Hence, the observed binding from the mixed-receptor surface can be attributed mostly to the trimolecular complex formation in the condition we used (Fig. 6). Our simultaneous display method allowed for control of receptor subunit frequency. This was important for β c cytokines, as IL5 and GM-CSF do not bind to β c independently (Fig. 2B and 5F), and increasing the amount of β c in the mixed-receptor surface was needed to increase the relative frequency of the trimolecular (cytokine- α - β c) interaction *vs* the bimolecular (cytokine- α) process. The combination of V5-tagged recombinant technology and SPR biosensor analysis provides a useful tool to study kinetics of multiple receptor assembly, and can be applied to any ligand-receptor system without the need to optimize the regeneration condition. The V5-tag anchoring method has the advantage, *versus* direct covalent immobilization of the subunits that has been used for IL2-receptor system [34] [35], that it allows optimizing the frequency of the receptor subunits on biosensor surface. This feature was not critical in the IL2 case, since IL2 interacts with finite affinity with each receptor subunit, but is less useful in the beta c cytokine case since direct interactions of cytokines with beta c alone are weak if they occur at all. Our method is similar to the previously-described simultaneous display of receptor subunits on sensor chips coated with lipid bilayers. Using this latter method, interactions have been evaluated kinetically for interferon and receptor subunits simultaneously anchored through fused His tags to exposed lipid head groups containing immobilized metal chelate [36] [37].

Of note, this latter method also enabled controlled variation of the ratios of receptor subunits on the sensor surface. Interestingly, the interferon study found that the ternary complex can be stabilized by fast re-association during the dissociation process, so-called kinetic stabilization, at a higher receptor surface concentrations. This result contrasts with our data for IL5 showing that the effect of increasing concentration of βc was saturated at a certain surface concentration (Fig 3A). The difference likely occurs because IL5 does not directly bind to βc subunit alone with measurable affinity, while interferon binds measurably to each of the immobilized subunits. The lipid bilayer display method, as ours, also suffers the limitation that the receptors are not full length and are not integrated into bilayers through transmembrane domains. Interaction with controllable receptor assemblies integrated into lipid bilayers ultimately could be achieved by such methods as cell fluorescence resonance energy transfer [41], but this method currently will not enable kinetic analysis of the type achievable using optical biosensor methodology.

4.2. Biological Implication of Slow-Dissociation Effect of βc Subunit

The βc subunit acts not only as a signal transducer but also as an affinity converter that enhances the binding affinity of βc cytokines (IL5, IL3 and GM-CSF) for their respective receptor complexes. Yet, how βc enhances the binding affinity of ligand-receptor complex has been unclear. In an effort to elucidate the mechanism and rationale of the affinity enhancement by βc , we investigated kinetics of either IL5 or GM-CSF binding to the individual (α or βc alone) and the mixed-receptor surfaces (α and βc together). Since formation and breakdown of protein complexes are controlled by such kinetic parameters as association and dissociation rate constants (k_{on} and k_{off}), these parameters are indispensable information for understanding the dynamic nature of ligand-receptor interaction. We found that the higher affinity of trimolecular vs bimolecular complex formation was predominantly due to the slower dissociation (smaller k_{off} value; Table 1), demonstrating the importance of βc -derived kinetic enhancement of cytokine-receptor binding affinity by decreasing the dissociation rate of cytokine-receptor complex. This slow-dissociation effect was abolished by alanine replacement of either Tyr18 or Tyr344, of βc , each of which constitutes a key part of a cytokine binding epitope (Figs. 4 and 5). From these data, we conclude that βc plays an important role in preventing ligand-receptor complexes from rapidly dissociating.

It has been believed that the receptor activation by βc cytokines is a sequential process that includes on the initial interaction of cytokine with a cytokine-specific α subunit, recruitment of βc into oligomeric receptor complexes, disulfide bond formation between α and βc subunits and the initiation of cytoplasmic phosphorylation events [38] [39] [40]. Subunits α and βc do not appear to preassemble in the absence of the ligand as judged from fluorescence resonance energy transfer studies on cell membranes [41]. Nonetheless, our SPR data infer that α and βc subunits could be physically associated or “pre-engaged” at least weakly on the biosensor surface. First, we found that IL5-IL5R α complex does not bind efficiently to the mixed α and βc surface (Fig. 3B). Second, binding data from the mixed surface fit well to a simple 1:1 binding model, and no improvement of fit could be achieved with the trimolecular stepwise model. Third, the association rate was slower for the trimolecular complex of IL5 than for the bimolecular interaction (Table 1). Physical association of subunits could cause steric hindrance and consequent slow association of ligand binding to the receptor. Whether physical receptor subunit association on the sensor surface results from weak, biologically relevant interaction of α and βc or from non-specific crowding on the biosensor surface cannot be differentiated at present. In any case, the finding that βc prevents the ligand-receptor complex from rapid dissociation once formed is clearcut and argues for a functional role of βc after the trimolecular complex formation in the receptor activation process. The complex stabilized by βc might be important to entrap the cytokine to enable structural reorganizations such as conformational change and disulfide bond formation. Previously, cellular experiments using

immunoprecipitation assay have shown that a disulfide bond can be formed between α and β c subunits and that this is required for the receptor activation of β c cytokine receptors [42] [43] [44]. However, it has been shown that a simple mixture of purified α/β c subunits with ligand does not yield a disulfide-bonded receptor complex [30]. These data suggest that some redox facilitators on the cells may be involved in this inter-subunit disulfide formation. If so, one would imagine that the complex stabilized by β c might allow the facilitators to have enough time to access α and β c subunits and form the disulfide bond between them.

Cellular binding assays have shown that GM-CSF binds to GMR α with a relatively low affinity, and that higher-affinity complexes are formed in the presence of β c [9]. In contrast, IL5 binds to IL5R α with a higher affinity, and only a relatively small affinity enhancement by β c has been observed in this case [11] [14]. In our biosensor assay, we found an analogous tendency that efficiency of affinity conversion by β c is greater for GM-CSF receptor vs that for IL5. Kinetic evaluation demonstrated that the difference in the efficiency between IL5 and GM-CSF systems arises mostly from the difference in the association rates (Table 1). It should be noted that the dissociation rates of the trimolecular interaction of both IL5 and GM-CSF were very slow and nearly the same (Table 1). This suggests a similarity of the binding interfaces of β c for IL5 and GM-CSF, because the dissociation rate of protein-protein interaction can be attributed to processes that destabilize the binding interface of the final complex. We further demonstrated that the slow-dissociation effects of β c were abolished by alanine replacement of either Tyr18 or Tyr344 residue of β c in both IL5 and GM-CSF systems. Although these tyrosine residues are distant in the primary sequence, Tyr18 and Tyr344 are clustered in the interface of D1 and D4 domains (Fig. 4A). Since Tyr18 and Tyr344 are highly solvent-accessible (41 and 60%, respectively) and hence do not reside in the hydrophobic core of the protein, it has been assumed that these residues are involved in the direct interaction with the ligands as opposed to conformational stabilization of remote binding sites. The importance of a tyrosine cluster for cytokine recognition also has been observed in the IL4-IL4R α interaction. The crystal structure of IL4-IL4R α complex showed that Tyr13 and Tyr183 from D1 and D2 domains, which constitute the CRM of IL4R α , make hydrogen-bond contacts with the side-chain carboxylate of Glu9 in the N-terminal helix of IL4 [45] [46]. Interestingly, the key contact residues of IL5 and GM-CSF for β c recognition are also glutamic acid residues, which are Glu13 and Glu21 in the N-terminal helices of IL5 and GM-CSF, respectively [47] [48]. Thus, it is tempting to speculate that the side chain of Glu13 of IL5 or Glu20 of GM-CSF might come into contact with the tyrosine cluster of β c in the trimolecular complexes. Although the detailed structural description of ligand-receptor complexes must await crystallographic determination of the complexes, our data strongly suggest that residues Tyr18 and Tyr344 of β c constitute a binding site for IL5 and GM-CSF that plays a critical role in the slow-dissociation of the cytokines.

Because IL5, IL3 and GM-CSF share a signaling subunit β c, they display broadly overlapping functions [49] [50]. However, specificity in signal transduction can be achieved through several mechanisms [51]. Firstly, the specific receptor subunits α for these cytokines are differentially expressed in different haematopoietic cells. The expression of IL5R α in humans is restricted to eosinophilic and basophilic lineages, whereas receptor α subunits for IL3 and GM-CSF are expressed on various lineages including eosinophils, basophils, monocyte/macrophages, dendritic cells, and early haematopoietic progenitors [12]. Although α subunits for IL5, IL3 and GM-CSF are all expressed in eosinophils and therefore these cytokines elicit similar responses on eosinophils [50], the biological effect of IL5 appears to have a greater quantitative impact on eosinophils than the others [7]. We found that IL5 binds to IL5R α with a higher binding affinity due to the 20-fold faster association rate (larger k_{on} value) than GM-CSF (Table 1). In other words, the fast association can facilitate IL5R α on the cell surface to capture the ligand. Lopez et al. have shown that IL5, IL3 and GM-CSF cross-compete for binding to the same cell [13]. For instance, GM-CSF cannot utilize β c on the cell once β c is utilized by IL5.

In our study, we demonstrated that βc can stabilize the ligand-receptor complexes which dissociate rapidly in the absence of βc . This slow-dissociation effect of βc might argue for how βc is utilized on the cell surface for the specific biological responses: selective βc usage can be controlled by sequestration in the stabilized trimolecular cytokine- $R\alpha$ - βc complexes when multiple receptor α subunits of βc cytokines are present on the eosinophils cell surface. The fast association of the IL5-IL5 $R\alpha$ interaction and the slow-dissociation effect of βc would provide an explanation for how IL5 can be more specific and dominant for activating eosinophils over the other competing βc cytokines.

Acknowledgements

This work was supported by National Institutes of Health Grants GM55648 and AI 40462. We thank Miss Nicoleta Economou for her assistance during a Ph.D student rotation.

Abbreviations

IL	interleukin
GM-CSF	granulocyte/macrophage-colony-stimulating factor
βc	common receptor β subunit
sβc	soluble form of βc
IL5$R\alpha$	interleukin 5 receptor α subunit
sIL5$R\alpha$	soluble form of IL5 $R\alpha$
GMRα	GM-CSF receptor α subunit
sGMRα	soluble form of GMR α
CRM	cytokine recognition motif
FnIII	fibronectin type III
SPR	surface plasmon resonance
RU	resonance unit
PBS	phosphate buffered saline

References

1. Heldin CH. Dimerization of cell surface receptors in signal transduction. *Cell* 1995;80:213–23. [PubMed: 7834741]
2. Arai KI, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T. Cytokines: coordinators of immune and inflammatory responses. *Annu Rev Biochem* 1990;59:783–836. [PubMed: 1695833]
3. Till S, Li B, Durham S, Humbert M, Assoufi B, Huston D, Dickason R, Jeannin P, Kay AB, Corrigan C. Secretion of the eosinophil-active cytokines interleukin-5, granulocyte/macrophage colony-stimulating factor and interleukin-3 by bronchoalveolar lavage CD4+ and CD8+ T cell lines in atopic asthmatics, and atopic and non-atopic controls. *Eur J Immunol* 1995;25:2727–31. [PubMed: 7589063]
4. Kay AB, Menzies-Gow A. Eosinophils and interleukin-5: the debate continues. *Am J Respir Crit Care Med* 2003;167:1586–7. [PubMed: 12796050]
5. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). *J Allergy Clin Immunol* 2004;113:11–28. [PubMed: 14713902]quiz 29
6. Leiferman KM, Gleich GJ. Hypereosinophilic syndrome: case presentation and update. *J Allergy Clin Immunol* 2004;113:50–8. [PubMed: 14713907]
7. Sanderson CJ. Interleukin-5, eosinophils, and disease. *Blood* 1992;79:3101–9. [PubMed: 1596561]
8. Rozwarski DA, Gronenborn AM, Clore GM, Bazan JF, Bohm A, Wlodawer A, Hatada M, Karplus PA. Structural comparisons among the short-chain helical cytokines. *Structure* 1994;2:159–73. [PubMed: 8069631]
9. Hayashida K, Kitamura T, Gorman DM, Arai K, Yokota T, Miyajima A. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. *Proc Natl Acad Sci U S A* 1990;87:9655–9. [PubMed: 1702217]
10. Kitamura T, Sato N, Arai K, Miyajima A. Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. *Cell* 1991;66:1165–74. [PubMed: 1833064]
11. Tavernier J, Devos R, Cornelis S, Tuypens T, Van der Heyden J, Fiers W, Plaetinck G. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF. *Cell* 1991;66:1175–84. [PubMed: 1833065]
12. Martinez-Moczygemba M, Huston DP. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. *J Allergy Clin Immunol* 2003;112:653–65. [PubMed: 14564341]quiz 666
13. Lopez AF, Vadas MA, Woodcock JM, Milton SE, Lewis A, Elliott MJ, Gillis D, Ireland R, Olwell E, Park LS. Interleukin-5, interleukin-3, and granulocyte-macrophage colony-stimulating factor cross-compete for binding to cell surface receptors on human eosinophils. *J Biol Chem* 1991;266:24741–7. [PubMed: 1761568]
14. Tavernier J, Tuypens T, Plaetinck G, Verhee A, Fiers W, Devos R. Molecular basis of the membrane-anchored and two soluble isoforms of the human interleukin 5 receptor alpha subunit. *Proc Natl Acad Sci U S A* 1992;89:7041–5. [PubMed: 1495999]
15. Kitamura T, Miyajima A. Functional reconstitution of the human interleukin-3 receptor. *Blood* 1992;80:84–90. [PubMed: 1377056]
16. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. *Proc Natl Acad Sci U S A* 1990;87:6934–8. [PubMed: 2169613]
17. Goodall GJ, Bagley CJ, Vadas MA, Lopez AF. A model for the interaction of the GM-CSF, IL-3 and IL-5 receptors with their ligands. *Growth Factors* 1993;8:87–97. [PubMed: 8466757]
18. Ishino T, Pasut G, Scibek J, Chaiken I. Kinetic interaction analysis of human interleukin 5 receptor alpha mutants reveals a unique binding topology and charge distribution for cytokine recognition. *J Biol Chem* 2004;279:9547–56. [PubMed: 14662768]
19. Takaki S, Murata Y, Kitamura T, Miyajima A, Tominaga A, Takatsu K. Reconstitution of the functional receptors for murine and human interleukin 5. *J Exp Med* 1993;177:1523–9. [PubMed: 8496674]
20. Scibek JJ, Evergren E, Zahn S, Canziani GA, Van Ryk D, Chaiken IM. Biosensor analysis of dynamics of interleukin 5 receptor subunit beta(c) interaction with IL5:IL5R(alpha) complexes. *Anal Biochem* 2002;307:258–65. [PubMed: 12202242]

21. Woodcock JM, Zacharakis B, Plaetinck G, Bagley CJ, Qiyu S, Hercus TR, Tavernier J, Lopez AF. Three residues in the common beta chain of the human GM-CSF, IL-3 and IL-5 receptors are essential for GM-CSF and IL-5 but not IL-3 high affinity binding and interact with Glu21 of GM-CSF. *Embo J* 1994;13:5176–85. [PubMed: 7957082]
22. Woodcock JM, Bagley CJ, Zacharakis B, Lopez AF. A single tyrosine residue in the membrane-proximal domain of the granulocyte-macrophage colony-stimulating factor, interleukin (IL)-3, and IL-5 receptor common beta-chain is necessary and sufficient for high affinity binding and signaling by all three ligands. *J Biol Chem* 1996;271:25999–6006. [PubMed: 8824238]
23. Murphy JM, Ford SC, Wiedemann UM, Carr PD, Ollis DL, Young IG. A novel functional epitope formed by domains 1 and 4 of the human common beta-subunit is involved in receptor activation by granulocyte macrophage colony-stimulating factor and interleukin 5. *J Biol Chem* 2003;278:10572–7. [PubMed: 12525483]
24. Murphy JM, Ford SC, Olsen JE, Gustin SE, Jeffrey PD, Ollis DL, Young IG. Interleukin-3 binding to the murine betaIL-3 and human betac receptors involves functional epitopes formed by domains 1 and 4 of different protein chains. *J Biol Chem* 2004;279:26500–8. [PubMed: 15060062]
25. Carr PD, Gustin SE, Church AP, Murphy JM, Ford SC, Mann DA, Woltring DM, Walker I, Ollis DL, Young IG. Structure of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. *Cell* 2001;104:291–300. [PubMed: 11207369]
26. Dowd CS, Leavitt S, Babcock G, Godillot AP, Van Ryk D, Canziani GA, Sodroski J, Freire E, Chaiken IM. Beta-turn Phe in HIV-1 Env binding site of CD4 and CD4 mimetic miniprotein enhances Env binding affinity but is not required for activation of co-receptor/17b site. *Biochemistry* 2002;41:7038–46. [PubMed: 12033937]
27. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. *Protein Sci* 1995;4:2411–23. [PubMed: 8563639]
28. Myszkka DG, Morton TA. CLAMP: a biosensor kinetic data analysis program. *Trends Biochem Sci* 1998;23:149–50. [PubMed: 9584619]
29. Morton TA, Myszkka DG, Chaiken IM. Interpreting complex binding kinetics from optical biosensors: a comparison of analysis by linearization, the integrated rate equation, and numerical integration. *Anal Biochem* 1995;227:176–85. [PubMed: 7668379]
30. McClure BJ, Hercus TR, Cambareri BA, Woodcock JM, Bagley CJ, Howlett GJ, Lopez AF. Molecular assembly of the ternary granulocyte-macrophage colony-stimulating factor receptor complex. *Blood* 2003;101:1308–15. [PubMed: 12393492]
31. Ishino T, Pillalamarri U, Panarello D, Bhattacharya M, Urbina C, Horvat S, Sarkhel S, Jameson B, Chaiken I. Asymmetric usage of antagonist charged residues drives interleukin-5 receptor recruitment but is insufficient for receptor activation. *Biochemistry* 2006;45:1106–15. [PubMed: 16430207]
32. Monfardini C, Ramamoorthy M, Rosenbaum H, Fang Q, Godillot PA, Canziani G, Chaiken IM, Williams WV. Construction and binding kinetics of a soluble granulocyte-macrophage colony-stimulating factor receptor alpha-chain-Fc fusion protein. *J Biol Chem* 1998;273:7657–67. [PubMed: 9516471]
33. Cunningham BC, Wells JA. Comparison of a structural and a functional epitope. *J Mol Biol* 1993;234:554–63. [PubMed: 7504735]
34. Myszkka DG, Arulanantham PR, Sana T, Wu Z, Morton TA, Ciardelli TL. Kinetic analysis of ligand binding to interleukin-2 receptor complexes created on an optical biosensor surface. *Protein Sci* 1996;5:2468–78. [PubMed: 8976555]
35. Rickert M, Boulanger MJ, Goriatcheva N, Garcia KC. Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its alpha, beta, and gamma (c) receptors. *J Mol Biol* 2004;339:1115–28. [PubMed: 15178252]
36. Lamken P, Lata S, Gavutis M, Piehler J. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. *J Mol Biol* 2004;341:303–18. [PubMed: 15312780]
37. Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, Van der Heyden J, Uze G, Schreiber G. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. *Mol Cell Biol* 2006;26:1888–97. [PubMed: 16479007]

38. Bagley, CJ.; Woodcock, JM.; Stomski, FC.; Lopez, AF. The Structural Basis for Interleukin-5 Receptor Assembly. New York: Marcel Dekker Inc; 1999.
39. D'Andrea RJ, Gonda TJ. A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit. *Exp Hematol* 2000;28:231–43. [PubMed: 10720688]
40. Ishino, T.; Robertsonm, N.; Chaiken, I. Cytokine Recognition by Human Interleukin-5 Receptor. In: Litwack, G., editor. *Vitamins and Hormones*. New York: Academic Press; 2005. p. 321–344.
41. Zaks-Zilberman, M.; Harrington, A.; Ishino, T.; Chaiken, I. American Society for Biochemistry and Molecular Biology. Washington DC: 2007. Monitoring ligand-dependent IL-5 receptor activation on cells using fluorescence resonance energy transfer.
42. Stomski FC, Sun Q, Bagley CJ, Woodcock J, Goodall G, Andrews RK, Berndt MC, Lopez AF. Human interleukin-3 (IL-3) induces disulfide-linked IL-3 receptor alpha- and beta-chain heterodimerization, which is required for receptor activation but not high-affinity binding. *Mol Cell Biol* 1996;16:3035–46. [PubMed: 8649415]
43. Stomski FC, Woodcock JM, Zacharakis B, Bagley CJ, Sun Q, Lopez AF. Identification of a Cys motif in the common beta chain of the interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 receptors essential for disulfide-linked receptor heterodimerization and activation of all three receptors. *J Biol Chem* 1998;273:1192–9. [PubMed: 9422786]
44. Le F, Stomski F, Woodcock JM, Lopez AF, Gonda TJ. The role of disulfide-linked dimerization in interleukin-3 receptor signaling and biological activity. *J Biol Chem* 2000;275:5124–30. [PubMed: 10671557]
45. Hage T, Sebald W, Reinemer P. Crystal structure of the interleukin-4/receptor alpha chain complex reveals a mosaic binding interface. *Cell* 1999;97:271–81. [PubMed: 10219247]
46. Zhang JL, Simeonowa I, Wang Y, Sebald W. The high-affinity interaction of human IL-4 and the receptor alpha chain is constituted by two independent binding clusters. *J Mol Biol* 2002;315:399–407. [PubMed: 11786020]
47. Tavernier J, Tuytens T, Verhee A, Plaetinck G, Devos R, Van der Heyden J, Guisez Y, Oefner C. Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist. *Proc Natl Acad Sci U S A* 1995;92:5194–8. [PubMed: 7761472]
48. Lopez AF, Shannon MF, Hercus T, Nicola NA, Cambareri B, Dottore M, Layton MJ, Eglinton L, Vadas MA. Residue 21 of human granulocyte-macrophage colony-stimulating factor is critical for biological activity and for high but not low affinity binding. *Embo J* 1992;11:909–16. [PubMed: 1532144]
49. Warren DJ, Moore MA. Synergism among interleukin 1, interleukin 3, and interleukin 5 in the production of eosinophils from primitive hemopoietic stem cells. *J Immunol* 1988;140:94–9. [PubMed: 3257232]
50. Miyajima A, Mui AL, Ogorochi T, Sakamaki K. Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5. *Blood* 1993;82:1960–74. [PubMed: 8400249]
51. Geijsen N, Koenderman L, Coffey PJ. Specificity in cytokine signal transduction: lessons learned from the IL-3/IL-5/GM-CSF receptor family. *Cytokine Growth Factor Rev* 2001;12:19–25. [PubMed: 11312115]
52. Koradi R, Billeter M, Wuthrich K. MOLMOL: a program for display and analysis of macromolecular structures. *J Mol Graph* 1996;14:51–5. 29–32. [PubMed: 8744573]

Figure 1. Expression and purification of soluble βc subunit

(A) Comparison of soluble form of human βc (s βc) used in the V5-tag anchoring binding assay with full length human βc composed of an extracellular region (from N-terminus; D1, D2, D3 and D4), a transmembrane (TM) region and a cytoplasmic (CP) region. The soluble form of βc corresponds to the extracellular region. V5 peptide (GKPIPPLLGLDST) and hexahistidine (HHHHHH) sequences (V5/His-tags) were fused at the C-terminal region, corresponding to TM region in the full-length receptor subunit. (B) Coomassie blue-stained SDS-PAGE and western blotting analyses of s βc : lane 1, molecular marker (Precision Plus Protein Standard, Bio-Rad); lane 2, purified s βc (50 mM DTT); lane 3, purified s βc (non-reducing); lane 4, western blotting of purified s βc by anti- βc antibody.

Figure 2. Kinetic analysis of IL5 binding behavior on individual and mixed-receptor surfaces
 (A) Overlay of real-time sensorgrams obtained from sequential injections of 5, 10, 20 and 40 nM IL5 over the sIL5R α -anchored surface, followed by injection of running buffer at 120 s. The rate constants were calculated by globally fitting the association phase (0 - 120 s) and dissociation phase (120 - 360 s) to a model for 1:1 simple binding. *Black and Red lines* show experimental and calculated sensorgrams, respectively. (B) A sensorgram from a single injection of 2 μ M IL5 over the s β c-anchored surface. (C) Overlay of sensorgrams obtained from sequential injections of 5, 10, 20 and 40 nM IL5 over the mixed-receptor surface of sIL5R α and s β c, followed by injection of running buffer. **Lower panels** show schematic diagrams of receptor components on the biosensor surface.

Figure 3. Control binding experiments for SPR biosensor trimolecular assays

(A) Binding kinetics at different ratios of receptor subunits. Mixtures of different ratios of sIL5R α and s β c were injected onto the anti-V5 antibody surface and then 10 nM of IL5 was injected over the mixed-receptor surfaces. The association (0 - 120 s) and dissociation (120 - 360 s) were measured and compared. Each sensorgram was normalized. (B) Inhibition of IL5 binding to the α and β c surface by IL5R α . The overlay of real-time sensorgrams shows sequential injections of the mixture of soluble α and β c subunits (0 s) and running buffer (120 s), followed by injections (315 s) of buffer (black), IL5 (1 μ M, blue) or IL5 and IL5R α mixture (1 μ M each, red).

Figure 4. Effect of βc mutation on IL5·IL5R α · βc complex formation

(A) IL5 binding residues of βc are shown in CPK (Corey, Pauling and Koltum) representation in the interface of D1 and D4 domains of the crystal structure of βc (Protein Data Bank accession code 1gh7) [25] and labeled by residue type and number. The molecular graphics figure was prepared by the program MOLMOL [52]. (B) Kinetic analysis of βc mutational variants. Overlay of real-time sensorgrams shows sequential injections of 5, 10, 20 and 40 nM IL5 over the mixed-receptor surface of such βc mutational variants as $\beta c(Y18A)$ (*upper*) and $\beta c(Y344A)$ (*lower*) together with sIL5R α , followed by injection of running buffer alone at 120 s. The rate constants were calculated by globally fitting the association (0 - 120 s) and

dissociation (120 – 360 s) phases to a model for 1:1 simple binding. *Black* and *Red lines* show experimental and calculated sensorgrams, respectively.

Figure 5. Kinetic analysis of GM-CSF binding and effect of βc mutation

(A) Schematic diagrams show the configuration of the biosensor surfaces comprised of sGMR α and s βc . (B–E) Overlay of real-time sensorgrams from sequential injections of 50, 100, 200 and 400 nM GM-CSF over the sGMR α (B), sGMR α -s βc (C), sGMR α -s βc (Y18A) (D) and sGMR α -s βc (Y344A) (E) surfaces. The rate constants were calculated by globally fitting the association (0 - 120 s) and dissociation (120 – 360 s) phases to a 1:1 binding model. Black and Red lines show experimental and calculated sensorgrams, respectively. (F) Real-time sensorgram from a single injection of 2 μ M GM-CSF over the s βc -anchored surface.

Figure 6. Idealized scheme of interaction of IL5 with IL5R α and β c on a dextran sensor chip surface Soluble IL5R α and excess amount of β c are co-anchored through the tight interaction between their C-terminal V5-tag and anti-V5 antibody immobilized on the flexible carboxymethylated dextran surface. IL5, sIL5R α , β c and anti-V5 antibody are shown as *grey, red blue and black* shapes, respectively. The dextran and gold surface of biosensor are shown as *green and orange* lines, respectively.

Table 1
Kinetic parameters of receptor binding of IL5 and GM-CSF

Receptor subunits	$k_{on} \times 10^{-6}$ ($M^{-1} s^{-1}$)	$k_{off} \times 10^3$ (s^{-1})	$K_d \times 10^9$ (M)	$K_d (\text{cellular})^I \times 10^9$ (M)
IL5R α	2.0 ± 0.2	6.1 ± 2	3.1 ± 0.5	1.0
IL5R α + β c	0.76 ± 0.2	0.95 ± 0.2	1.3 ± 0.2	0.29
IL5R α + β c(Y18A)	1.3 ± 0.4	4.0 ± 2	3.0 ± 0.5	-
IL5R α + β c(Y344A)	1.1 ± 0.1	3.9 ± 0.8	3.6 ± 0.3	-
GMR α	0.11 ± 0.1	11 ± 0.4	100 ± 13	12
GMR α + β c	0.22 ± 0.09	1.5 ± 0.4	6.9 ± 0.1	0.13
GMR α + β c(Y18A)	0.082 ± 0.004	13 ± 3	140 ± 12	-
GMR α + β c(Y344A)	0.079 ± 0.003	8.8 ± 0.3	110 ± 6	-

* Kinetic parameters were generated by using a model for 1:1 binding combined with mass transport limitation factor.

^I Equilibrium dissociation constants determined as described [21] for cytokine binding to receptor subunits expressed on cells.